Association between dietary magnesium intake and epilepsy: The mediating role of composite dietary antioxidant index based on a cross-sectional study
Lai Y, Zhou Y, Yang L, Yin J
IBRO neuroscience reports · 2 citas
Cómo se estudió
- Diseño
- Estudio transversal (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Chengdu Medical College
- Subvenciones
- Chengdu Medical College (23LHHGYSD26)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-02-05 · IBRO Neurosci Rep · vol. 20 · págs. 244–251
- Editorial
- Elsevier BV
- Citado
- 2 citas · más que el 96% de estudios similares · 9.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 33 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Magnesium in Health and Disease · Pharmacological Effects and Toxicity Studies · Parathyroid Disorders and Treatments
- Palabras clave
- Inflammation, Antioxidant, Magnesium, Socioeconomic status, Index (typography), Prospective cohort study
4 autores
- Yali Lai🇨🇳China National Nuclear Corporation
- Yi Zhou🇨🇳China National Nuclear Corporation
- Le Yang🇨🇳China National Nuclear Corporation
- Jierong Yin🇨🇳China National Nuclear Corporation
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Epilepsy affects 1.2 % of the US population, with one-third of cases being drug-resistant. Magnesium modulates neuronal excitability, and dietary insufficiency may elevate seizure risk. Systemic inflammation, quantified by the Composite Dietary Antioxidant Index (CDAI), represents a plausible mediator, but population-level evidence remains limited.
Objective
To investigate associations between dietary magnesium intake and epilepsy prevalence, assess CDAI-mediated pathways, and identify high-benefit subgroups.
Methods
Cross-sectional analysis included 33,486 adults (≥20 years) from NHANES 2013-2018. Dietary magnesium intake was derived from two 24-hour recalls and analyzed continuously (per SD) and categorically (quartiles). Epilepsy was self-reported. CDAI integrated six micronutrient intakes. Weighted multivariable logistic regression evaluated magnesium-epilepsy associations, adjusted for sociodemographic, clinical, and dietary covariates. Mediation analysis quantified CDAI's role.
Results
After full adjustment, each SD increase in magnesium intake was associated with 62 % lower epilepsy prevalence (OR = 0.38, 95 % CI: 0.21-0.70, p = 0.004). Quartile analysis revealed a significant inverse trend (p-trend = 0.032), with Q4 (highest intake) exhibiting the lowest risk (OR = 0.38, 95 % CI: 0.12-1.15). CDAI mediated 50.1 % of magnesium's protective effect (indirect effect: -0.478, 95 % CI: -1.031 to -0.166; p < 0.001). Stronger inverse associations occurred in Non-Hispanic Black (OR = 0.32, 95 % CI: 0.11-0.94) and Mexican American (OR = 0.35, 95 % CI: 0.16-0.76) individuals (p-interaction = 0.009) and those with obesity (OR = 0.26, 95 % CI: 0.10-0.68).
Conclusion
Higher dietary magnesium intake is associated with significantly reduced epilepsy prevalence in US adults, with half of this effect mediated by attenuated inflammation (CDAI). Populations with elevated inflammation burdens or socioeconomic disadvantages may derive particular benefit. These findings support magnesium-rich diets as a potential preventive strategy and warrant prospective validation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.